TMDX TransMedics Group, Inc.
FY2025 10-K
TransMedics Group, Inc. (TMDX) filed its fiscal year 2025 10-K annual report with the SEC on Feb 24, 2026. This page provides AI-powered analysis of the filing, including business overview, management discussion, risk factors, and key financial metrics from XBRL data.
AI Filing AnalysisFY2025 10-K
Business Overview
- • Core business: Medical technology company providing OCS platform and NOP services to improve organ transplant therapy for heart, lung, and liver
- • New emphasis on NOP expansion with acquisition of Summit Aviation and 22 fixed-wing aircraft to enhance national organ transportation logistics
Management Discussion & Analysis
- • No revenue or profitability data disclosed in this section
- • Convertible Senior Notes issued $460M, net proceeds $393.3M after $52.1M capped call costs and $14.6M issuance costs, interest 1.50%
Risk Factors
- • Leverage risk from $460M Notes issued May 2023, 1.50% interest, maturing June 2028
- • Macroeconomic exposure to long-term Somerville lease, $23.9M annual base rent starting 2028, escalating 2-3% annually
Financial SummaryXBRL
Revenue
$605M
Net Income
$190M
Gross Margin
59.9%
Operating Margin
17.9%
Net Margin
31.4%
ROE
40.2%
Total Assets
$1.1B
EPS (Diluted)
$4.87
Operating Cash Flow
$193M
Source: XBRL data from TransMedics Group, Inc. FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on TransMedics Group, Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.